A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma

被引：149

作者：

Molina, Arturo ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Cougar Biotechnol, Los Angeles, CA 90024 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2008年 / 59卷

关键词：

monoclonal antibody; immunotherapy; CD20; antigen; follicular lymphoma; diffuse large B cell lymphoma;

D O I：

10.1146/annurev.med.59.060906.220345

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The anti-CD20 monoclonal antibody rituximab, first approved for clinical use in 1997, has changed the standard of care for many patients with non-Hodgkin's lymphoma (NUL). Recent data from large randomized clinical trials confirm that the addition of rituximab to standard chemotherapy regimens (chemoimmunotherapy) improves both response rates and survival outcomes in patients with follicular NHL and diffuse large B cell lymphoma (DLBCL), the two most common subtypes of NHL. Population-based analyses have found substantial improvements in NHL survival over the past decade; studies indicate that rituximab has favorably altered the long-term prognosis of follicular NHL and DLBCL patients. This review discusses the clinical development of rituximab-based therapies for patients with low-grade or follicular NHL and newly diagnosed DLBCL, highlighting recent key randomized trials with a focus on survival outcomes.

引用

页码：237 / 250

页数：14

共 48 条

[21] Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma:: chemotherapy versus chemotherapy plus rituximab [J].

Herold, M ;

Dölken, G ;

Fiedler, F ;

Franke, A ;

Freund, M ;

Helbig, W ;

Pasold, R .

ANNALS OF HEMATOLOGY, 2003, 82 (02) :77-79

[22] Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study [J].

Herold, Michael ;

Haas, Antje ;

Srock, Stefanie ;

Neser, Sabine ;

Al-Ali, Kathrin Haifa ;

Neubauer, Andreas ;

Doelken, Gottfried ;

Naumann, Ralph ;

Knauf, Wolfgang ;

Freund, Mathias ;

Rohrberg, Robert ;

Hoeffken, Klaus ;

Franke, Astrid ;

Ittel, Thomas ;

Kettner, Erika ;

Haak, Ursula ;

Mey, Ulrich ;

Klinkenstein, Christian ;

Assmann, Michael ;

von Gruenhagen, Ullrich .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1986-1992

[23] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[24]

HOCHSTER HS, 2005, BLOOD, V106, P349

[25] Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia [J].

Keating, MJ ;

O'Brien, S ;

Albitar, M ;

Lerner, S ;

Plunkett, W ;

Giles, F ;

Andreeff, M ;

Cortes, J ;

Faderl, S ;

Thomas, D ;

Koller, C ;

Wierda, W ;

Detry, MA ;

Lynn, A ;

Kantarjian, H .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4079-4088

[26] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG) [J].

Lenz, G ;

Dreyling, M ;

Hoster, E ;

Wörmann, B ;

Dührsen, U ;

Metzner, B ;

Eimermacher, H ;

Neubauer, A ;

Wandt, H ;

Steinhauer, H ;

Martin, S ;

Heidemann, E ;

Aldaoud, A ;

Parwaresch, R ;

Hasford, J ;

Unterhalt, M ;

Hiddemann, W .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1984-1992

[27]

Maloney DG, 1997, BLOOD, V90, P2188

[28] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J].

Marcus, R ;

Imrie, K ;

Belch, A ;

Cunningham, D ;

Flores, E ;

Catalano, J ;

Solal-Celigny, P ;

Offner, F ;

Walewski, J ;

Raposo, J ;

Jack, A ;

Smith, P .

BLOOD, 2005, 105 (04) :1417-1423

[29]

Marcus RE, 2006, BLOOD, V108, p146A

[30] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

← 1 2 3 4 5 →